Summit Therapeutics Inc vs Sasol Ltd. American Depositary Shares — how do they compare? Summit Therapeutics Inc trades at $17.27 (market cap $14.33B), while Sasol Ltd. American Depositary Shares trades at $15.05 (market cap $9.25B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Sasol Ltd. American Depositary Shares is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Sasol Ltd. American Depositary Shares for 0 Days on average.
| SMMT | SSL | |
|---|---|---|
Market Cap | $14.33B | $9.25B |
Volume | 8,167,213 | 1,222,173 |
Sector | Health | Basic Materials |
52-Week High | $26.38 | $15.14 |
52-Week Low | $12.43 | $5.33 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $13.66B | $12.97B |
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% today, with a bullish technical signal from moving averages and a consensus analyst price target of $29.33. The stock has surged recently following a $2 billion strategic equity investment from AstraZeneca and expanded clinical collaborations. However, the company remains pre-revenue with significant losses, reflected in a negative ROE of -192.5% and negative EBITDA of -$1.08 billion for 2025.
The outlook is driven by clinical progress for ivonescimab, but high execution risk and cash burn necessitate close monitoring. Investment opportunity hinges on successful drug development, while key risks include trial outcomes and funding needs. The stock offers high-risk, high-reward potential based on pipeline milestones.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →Sasol Limited is a Johannesburg-headquartered chemicals and energy company that uses its proprietary Fischer-Tropsch technology to convert coal, natural gas, and crude-oil feedstocks into fuels and chemical products such as polymers, solvents, surfactants, and ammonia, with operations across Southern Africa and international chemical manufacturing sites, including in US.
Read more on SSL →